These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 30467378)

  • 1. Conditional knockout of SHP2 in ErbB2 transgenic mice or inhibition in HER2-amplified breast cancer cell lines blocks oncogene expression and tumorigenesis.
    Zhao H; Martin E; Matalkah F; Shah N; Ivanov A; Ruppert JM; Lockman PR; Agazie YM
    Oncogene; 2019 Mar; 38(13):2275-2290. PubMed ID: 30467378
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Inhibition of the transcriptional kinase CDK7 overcomes therapeutic resistance in HER2-positive breast cancers.
    Sun B; Mason S; Wilson RC; Hazard SE; Wang Y; Fang R; Wang Q; Yeh ES; Yang M; Roberts TM; Zhao JJ; Wang Q
    Oncogene; 2020 Jan; 39(1):50-63. PubMed ID: 31462705
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tyrosine phosphatase SHP2 promotes breast cancer progression and maintains tumor-initiating cells via activation of key transcription factors and a positive feedback signaling loop.
    Aceto N; Sausgruber N; Brinkhaus H; Gaidatzis D; Martiny-Baron G; Mazzarol G; Confalonieri S; Quarto M; Hu G; Balwierz PJ; Pachkov M; Elledge SJ; van Nimwegen E; Stadler MB; Bentires-Alj M
    Nat Med; 2012 Mar; 18(4):529-37. PubMed ID: 22388088
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SHP2 acts both upstream and downstream of multiple receptor tyrosine kinases to promote basal-like and triple-negative breast cancer.
    Matalkah F; Martin E; Zhao H; Agazie YM
    Breast Cancer Res; 2016 Jan; 18(1):2. PubMed ID: 26728598
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Overexpression of miR-489 derails mammary hierarchy structure and inhibits HER2/neu-induced tumorigenesis.
    Patel Y; Soni M; Awgulewitsch A; Kern MJ; Liu S; Shah N; Singh UP; Chen H
    Oncogene; 2019 Jan; 38(3):445-453. PubMed ID: 30104710
    [TBL] [Abstract][Full Text] [Related]  

  • 6. HER2 regulates the mammary stem/progenitor cell population driving tumorigenesis and invasion.
    Korkaya H; Paulson A; Iovino F; Wicha MS
    Oncogene; 2008 Oct; 27(47):6120-30. PubMed ID: 18591932
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular mechanism for SHP2 in promoting HER2-induced signaling and transformation.
    Zhou X; Agazie YM
    J Biol Chem; 2009 May; 284(18):12226-34. PubMed ID: 19261604
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of SHP2 tyrosine phosphatase promotes the tumorigenesis of breast carcinoma.
    Hu Z; Fang H; Wang X; Chen D; Chen Z; Wang S
    Oncol Rep; 2014 Jul; 32(1):205-12. PubMed ID: 24858400
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The glucose transporter GLUT1 is required for ErbB2-induced mammary tumorigenesis.
    Wellberg EA; Johnson S; Finlay-Schultz J; Lewis AS; Terrell KL; Sartorius CA; Abel ED; Muller WJ; Anderson SM
    Breast Cancer Res; 2016 Dec; 18(1):131. PubMed ID: 27998284
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Oncogenic and tumor-suppressive mouse models for breast cancer engaging HER2/neu.
    Fry EA; Taneja P; Inoue K
    Int J Cancer; 2017 Feb; 140(3):495-503. PubMed ID: 27553713
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Increased erbB3 promotes erbB2/neu-driven mammary tumor proliferation and co-targeting of erbB2/erbB3 receptors exhibits potent inhibitory effects on breast cancer cells.
    Lyu H; Huang J; Edgerton SM; Thor AD; He Z; Liu B
    Int J Clin Exp Pathol; 2015; 8(6):6143-56. PubMed ID: 26261492
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A novel double-negative feedback loop between miR-489 and the HER2-SHP2-MAPK signaling axis regulates breast cancer cell proliferation and tumor growth.
    Patel Y; Shah N; Lee JS; Markoutsa E; Jie C; Liu S; Botbyl R; Reisman D; Xu P; Chen H
    Oncotarget; 2016 Apr; 7(14):18295-308. PubMed ID: 26918448
    [TBL] [Abstract][Full Text] [Related]  

  • 13. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
    Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
    Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neratinib is effective in breast tumors bearing both amplification and mutation of ERBB2 (HER2).
    Cocco E; Javier Carmona F; Razavi P; Won HH; Cai Y; Rossi V; Chan C; Cownie J; Soong J; Toska E; Shifman SG; Sarotto I; Savas P; Wick MJ; Papadopoulos KP; Moriarty A; Cutler RE; Avogadri-Connors F; Lalani AS; Bryce RP; Chandarlapaty S; Hyman DM; Solit DB; Boni V; Loi S; Baselga J; Berger MF; Montemurro F; Scaltriti M
    Sci Signal; 2018 Oct; 11(551):. PubMed ID: 30301790
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Protein tyrosine kinase 6 promotes ERBB2-induced mammary gland tumorigenesis in the mouse.
    Peng M; Ball-Kell SM; Tyner AL
    Cell Death Dis; 2015 Aug; 6(8):e1848. PubMed ID: 26247733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. ADAMTS18 deficiency associates extracellular matrix dysfunction with a higher risk of HER2-positive mammary tumorigenesis and metastasis.
    Nie J; Dang S; Zhu R; Lu T; Zhang W
    Breast Cancer Res; 2024 Jan; 26(1):19. PubMed ID: 38287441
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A role for the scaffolding adapter GAB2 in breast cancer.
    Bentires-Alj M; Gil SG; Chan R; Wang ZC; Wang Y; Imanaka N; Harris LN; Richardson A; Neel BG; Gu H
    Nat Med; 2006 Jan; 12(1):114-21. PubMed ID: 16369543
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Antitumor activity of phenethyl isothiocyanate in HER2-positive breast cancer models.
    Gupta P; Srivastava SK
    BMC Med; 2012 Jul; 10():80. PubMed ID: 22824293
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Targeting Gi/o protein-coupled receptor signaling blocks HER2-induced breast cancer development and enhances HER2-targeted therapy.
    Lyu C; Ye Y; Lensing MM; Wagner KU; Weigel RJ; Chen S
    JCI Insight; 2021 Sep; 6(18):. PubMed ID: 34343132
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Loss of Nrdp1 enhances ErbB2/ErbB3-dependent breast tumor cell growth.
    Yen L; Cao Z; Wu X; Ingalla ER; Baron C; Young LJ; Gregg JP; Cardiff RD; Borowsky AD; Sweeney C; Carraway KL
    Cancer Res; 2006 Dec; 66(23):11279-86. PubMed ID: 17145873
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.